Functional heterogeneity of vaccine-induced CD8+ T cells

Journal of Immunology

Volumn 168, Issue 11, 2002, Pages 5933-5942

  Monsurrò, Vladia ^a   Nagorsen, Dirk ^a   Wang, Ena ^a   Provenzano, Maurizio ^a   Dudley, Mark E ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

EID: 0036604134     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.11.5933     Document Type: Article

References (53)

1. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
2. Increased vaccinespecific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
3. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
4. Kinetics of TCR use in response to repeated epitope-specific immunization
5. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
6. Ex vivo IFN-γ secretion by circulating CD8 T lymphocytes: Implications of a novel approach for T cell monitoring in infectious and malignant diseases
7. + T cells
8. + T cells produce antiviral cytokines but are impaired in cytolytic function
9. + T cells
10. - human T cells
11. - cells are induced by antigen and evolve through extensive rounds of division
12. + T cells in healthy and immunosuppressed virus carriers
13. + cells in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: Correlation with HTLV-1 provirus load
14. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
15. Skewed maturation of memory HIV-specific CD8 T lymphocytes
16. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues
17. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
18. Phototyping: Comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP)
19. T-cell clones from melanoma patients immunized against an anchor modified gp100 peptide display discordant effector phenotypes
20. Therapeutic reconstitution of human viral immunity by adoptive transfer of cytotoxic T lymphocyte clones
21. Expression cloning of a human DNA repair gene involved in xeroderma pigmentosum group C
22. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes
23. Selective human leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells
24. Phenotypic analysis of antigen-specific T lymphocytes
25. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo
26. Laser scanner cytometer evaluation of MART-1, gp100 and HLA-A2 expression in melanoma metastases
27. Induction of tumor reactive CTL from peripheral blood and tumor infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
28. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells
29. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
30. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model
31. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response
32. Fas-Mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
33. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
34. Expansion and functional maturation of human tumor antigen-specific CD8* T cells after vaccination with antigenic peptide
35. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
36. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
37. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
38. An intronic mutation responsible for a low level of expression of an HLA-A*24 allele
39. + cancers
40. Clonal expansion of melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
41. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
42. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases
43. Functional analysis of antigenspecific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
44. Intensity of the vaccine-elicited immune response determines tumor clearance
45. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
46. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family
47. Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen
48. CD27 is required for generation and long-term maintenance of T cell immunity
49. + pool with distinct phenotypic and migratory characteristics
50. Is cancer dangerous to the immune system?
51. An innate sense of danger
52. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
53. Localization dose and time of antigens determine immune reactivity